Roxbury Financial LLC Acquires Shares of 2,021 Amgen Inc. (NASDAQ:AMGN)

Roxbury Financial LLC acquired a new stake in Amgen Inc. (NASDAQ:AMGN) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,021 shares of the medical research company’s stock, valued at approximately $572,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Capital Performance Advisors LLP acquired a new stake in Amgen in the third quarter worth $25,000. Legacy Investment Solutions LLC acquired a new stake in Amgen in the third quarter worth $29,000. Heck Capital Advisors LLC acquired a new stake in Amgen in the fourth quarter worth $36,000. PrairieView Partners LLC raised its holdings in Amgen by 118.3% in the fourth quarter. PrairieView Partners LLC now owns 179 shares of the medical research company’s stock worth $46,000 after purchasing an additional 97 shares during the period. Finally, Wingate Wealth Advisors Inc. acquired a new stake in Amgen in the fourth quarter worth $52,000. 76.50% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on AMGN. Wells Fargo & Company cut their target price on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a report on Friday, January 10th. Wolfe Research began coverage on shares of Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. Leerink Partners cut their target price on shares of Amgen from $349.00 to $302.00 in a report on Wednesday, November 27th. Jefferies Financial Group restated a “buy” rating and set a $380.00 price objective on shares of Amgen in a report on Tuesday, November 12th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on shares of Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $314.09.

Amgen Stock Down 2.0 %

Amgen stock opened at $291.16 on Friday. The company has a fifty day simple moving average of $273.75 and a 200 day simple moving average of $302.14. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The company has a market cap of $156.51 billion, a P/E ratio of 38.56, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. Research analysts anticipate that Amgen Inc. will post 20.59 earnings per share for the current fiscal year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.27%. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is 119.21%.

Insider Activity

In related news, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total transaction of $2,585,603.09. Following the completion of the sale, the executive vice president now owns 44,186 shares of the company’s stock, valued at approximately $13,025,590.94. The trade was a 16.56 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Jonathan P. Graham sold 25,045 shares of Amgen stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the sale, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at $8,496,669.44. The trade was a 46.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 35,405 shares of company stock valued at $10,410,596 in the last quarter. Company insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.